|
|
|
|
|
Peginterferon alfa-2a
drug data and news
Peginterferon alfa-2a drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Peginterferon alfa-2a | ||
| Brand Names/Synonyms | Interferon alpha-2 precursor;Interferon alpha-A;LeIF A; Pegasys (Hoffman-La Roche Inc) | ||
| Indication | For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma | ||
| Sponsored links | Description | Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol (PEG) chain. The PEG moiety is linked at a single site to the interferon alfa moiety via a stable amide bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 daltons. Interferon alfa-2a is produced using recombinant DNA technology in which a cloned human leukocyte interferon gene is inserted into and expressed in Escherichia coli. 165 amino acids. PEGylated to extend serum half life | |
| Pharmacology | Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R. | ||
| Mechanism Of Action | Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta. | ||
| Peginterferon alfa-2a News (When available) |
Human Genome Sciences Presents Interim Results of Phase 2b Trial ... May 1, 2006 Chronic Hepatitis B Patients Still in Remission Two Years After ... Apr 28, 2006 New PEGASYS(R) Trial Shows Six Months of Treatment is Optimal for ... May 1, 2006 Roche's Innovative Oral Polymerase Inhibitor Shows Strong ... May 1, 2006 New Oral Polymerase Inhibitor Shows Promising Results in Chronic ... Apr 29, 2006 ΞΕÎ?Η ΔΗΜΟΣΙΕΥΣΗ-ΑÎ?ΑΚΟΙÎ?ΩΣΗ ΤΥΠΟΥ-PRN ... Apr 27, 2006 PEGASYS(R) ACCELERATE Trial Shows Six Months of Treatment Is ... Apr 29, 2006 The ticking time bomb of liver disease May 2, 2006 Roche Oral Drug Shows Promise in Hepatitis C May 5, 2006 Roche study shows hepatitis C patients need six months of ... May 3, 2006 COMUNICADO: Pacientes de Hepatitis B crónica permanecen en estado ... Apr 27, 2006 New Data Highlight Anti-HCV Activity of Investigational Oral ... Apr 26, 2006 Higher Dose COPEGUS(R) 400mg Tablets Approved in the Netherlands ... Apr 23, 2006 | ||
| Dosage Forms | SOLUTION | ||
| Drug_Category | Antiviral Agents; Immunomodulatory Agents; Antineoplastic Agents; interferons (08:18.20) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | PEGylated human interferon alpha 2a | ||
| Chemical Formula | C860H1353N227O255S9 | ||
| Molecular Weight | 19241.1 | ||
| Smiles String | Not Available | ||
| Melting Point | 61 oC (Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999))Davis JM, Narachi MA, Levine HL, Alton NK, Arakawa T. Conformation and stability of two recombinant human interferon-alpha analogs. Int J Pept Protein Res. 1987 Jun;29(6):685-91. | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.336 | ||
| Isoelectric Point | 5.99 | ||
| Biotransformation | Not Available | ||
| Half Life | 50-140 hrs | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.rxlist.com/cgi/generic3/pegasys.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00043 | ||
| CAS Registry Number | 198153-51-4 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA10152 | ||
| SwissProt ID | IFNA2_HUMAN (P01563) | ||
| GenBank ID | J00207 | ||
| Drug ID Number [DIN] | 2248077 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |